Patients with mast cell disorders can experience symptoms affecting many different parts of the body, including itching, flushing, hives, abdominal discomfort, diarrhea, nasal symptoms, headaches, and episodes of lightheadedness or rapid heartbeat. Treatment often focuses on blocking the substances released by mast cells and reducing their effects on the body. One medication sometimes used as […]
MCAS Treatment: Medication Options for Mast Cell Activation Syndrome
Mast Cell Activation Syndrome (MCAS) is a condition in which mast cells release chemical mediators, such as histamine, leukotrienes, and prostaglandins, inappropriately or excessively. These chemicals can cause symptoms involving several parts of the body, including the skin, gastrointestinal tract, lungs, and cardiovascular system. Possible symptoms include: Flushing, itching, or hives Swelling Abdominal cramping, nausea, […]
Utuly 13.2 mg Intranasal Epinephrine by Bryn Pharma: Advancements in Non-Injection Anaphylaxis Management
Anaphylaxis is a severe, life-threatening allergic reaction that necessitates immediate treatment with epinephrine. While intramuscular epinephrine is the standard treatment, the advent of intranasal epinephrine offers a promising alternative. Bryn Pharma has developed Utuly 13.2 mg Intranasal Epinephrine, a novel formulation designed for non-invasive administration. This article reviews the pharmacological characteristics, clinical efficacy, safety profile, […]
Roflumilast (Zoryve) approved for Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by intense pruritus, erythema, and eczema. Affecting millions worldwide, it poses significant challenges due to its relapsing nature and impact on quality of life. Recent advancements in therapeutic options have led to the approval of roflumilast, a phosphodiesterase-4 (PDE4) inhibitor, for the treatment of mild […]
Dr. Alan Khadavi discusses Asthma with Health Central
Dr. Alan Khadavi recently contributed to the medical articles on the following asthma topics with Health Central What’s the Difference Between Advair and Flovent for Asthma? Pulmicort vs. Symbicort for Asthma: What’s the Difference? Ventolin vs. Atrovent for Asthma: How Are They Different? Can You Take Advair and Spiriva Together for Asthma?
Is Benadryl Safe to use, or is it Time to Move on?
Is Benadryl a safe medication to use? Benadryl or diphenhydramine has been available since 1946, before drugs were required to pass rigorous testing. Benadryl is commonly used and it is the most commonly recommended antihistamine for children over the past several years by physicians and pharmacists. Benadryl will frequently be chosen because of brand recognition […]
Roflumilast and Tapinarof; Emerging Therapies for Atopic Dermatitis
Roflumilast and Tapinarof are 2 emerging topical therapies that have completed or have ongoing phase 3 clinical trials, with the possibility of approval in 2022. Roflumilast is a more potent PDE4 inhibitor than crisaborloe (Eucrisa) with fewer local reactions. Tapinarof, the first therapeutic arylhydocarbon modulating agent for which the only associated local effect is noninfectious […]
Asivatrep a new topical treatment for Eczema
Asivatrep is a new potential treatment for eczema (atopic dermatitis). Atopic dermatitis is a chronic inflammatory itchy skin disease that affects up to 25% of children and 10% of adults. The cause is complex and multifactorial. Currently there are few classes of topical medications to treat it. Steroids Calcineurin inhibitors (Elidel, Protopic) Phosphodiesterase 4 inhibitors Eucrisa […]
PEG Allergy and Vaccine Allergy
PEG allergy has become an important topic since the COVID-19 vaccine rollout. There are 2 messenger RNA vaccines that have been approved in multiple countries around the world. Pfizer Covid Vaccine and Allergy Moderna Covid Vaccine and Allergy There are 3 adenovirus vector vaccines as well. Johnson and Johnson Covid Vaccine and Allergy Since the vaccine […]
Opzelura (ruxolitinib) for Eczema
Opzelura (ruxolitinib) has been FDA approved for eczema. Opzelura is a topical JAK inhibitor, and its indicated for short term use in patients 12 and up who have mild to moderate atopic dermatitis. It is the first topical janus kinase inhibitor approved in the United States. Currently for atopic dermatitis topical treatment, the mainstay of […]